Category Archives: HGH

News Release Wednesday, December 9, 2020 Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium. Continue reading →

BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd Continue reading →

University of Leeds research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumour using antibodies. Microbubblesaresmallmanufacturedsphereshalf the sizeof a red blood cell- andscientists believe they can be used to transport drugs tohighlyspecific locations within the body. The findings are published inthe journalTheranostics Continue reading →

Human Growth Hormone Drugs Market UpMarketResearch, 20-09-2020: The research report on the Human Growth Hormone Drugs Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. Continue reading →

The 1988 Olympics in Seoul, Korea, were rife with controversy. Track, in particular, experienced notable issues with potential PED abuse. Continue reading →

It's not easy to build muscle. Continue reading →

Read Time: Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study atESMO 2020. (1) This is the first time in more than 20 years that we have seen an advance in the adjuvant treatment of this form of breast cancer, said lead author Prof Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, UK. He explained that hormone receptor positive breast cancer is the commonest form of breast cancer, affecting 70% of patients, with most being diagnosed with early disease. Continue reading →

Global Anti-Aging Products Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential. Anti-Aging Products Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025 The study of Anti-Aging Products market is a compilation of the market of Anti-Aging Products broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Anti-Aging Products industry from a variety of data points that are collected through reputable and verified sources. Continue reading →

Adding the CDK4/6 inhibitor abemaciclib (Verzenio) to endocrine therapy significantly reduces the risk of early recurrence in high-risk hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, suggests a preplanned interim analysis of a phase 3 trial. Continue reading →

Global Anti-Aging Products and Therapies Market 2020 by Company, Type and Application, Forecast to 2025 offers a complete examination of industry status and standpoint of significant areas dependent on factors such as central participants, nations, item types, and end enterprises. The report contains an analysis of the present and future state of the industry. The report provides clients with crucial insights into the market. Continue reading →